Search

Calculation of JPX-Nikkei Index 400 and JPX-Nikkei Mid and Small Cap Index in Relation to Shares of Takeda Pharmaceutical Company Limited and LIFULL Co., Ltd. | Japan Exchange Group Dec. 17, 2018 TSE Calculation of JPX-Nikkei Index 400 and JPX-Nikkei Mid and Small Cap Index in Relation to Shares of Takeda Pharmaceutical Company Limited and LIFULL Co., Ltd. Tweet Takeda Pharmaceutical Company Limited (Code: 4502), a constituent of JPX-Nikkei Index 400, and LIFULL Co., Ltd. (Code: 2120), a constituent of JPX-Nikkei Mid and Small Cap Index, are respectively scheduled to issue new shares to be additionally listed on Tokyo Stock Exchange, Inc. on January 10, 2019. In connection with the additional listing of these new shares, the calculation of these indices shall be handled as indicated in the table below, taking into consideration factors such as convenience for indices users and the fact that the ...

1 December 17, 2018 Tokyo Stock Exchange, Inc. Nikkei Inc. Revision of Guidebook for JPX-Nikkei Index 400 and JPX-Nikkei Mid and Small Cap Index The guidebooks for JPX-Nikkei Index 400 and JPX-Nikkei Mid and Small Cap Index, which are jointly calculated by Tokyo Stock Exchange, Inc. (TSE) and Nikkei Inc. (Nikkei) have been revised as indicated below. 1. Key revisions to JPX-Nikkei Index 400 (1) Criteria used for determining qualitative scores Among the criteria used for determining qualitative scores, those under "Disclosure of English earnings information" will be revised as follows. Title New Old III.JPX-Nikkei Index 400 Constituent Selection 1.(2)⑤ (Item) Disclosure of English earnings information and/or Corporate Governance Report (Criteria) English documents regarding the most recent earnings information and/or Corporate Governance Report are disclosed via TDnet (Company Announcements Distribution Service in English) at the time of the base date (...

JPX-Nikkei Index 400 Guidebook December 17, 2018 Tokyo Stock Exchange, Inc. Nikkei Inc. Published: December 17, 2018 DISCLAIMER: This translation may be used for reference purposes only. This English version is not an official translation of the original Japanese document. In cases where any differences occur between the English version and the original Japanese version, the Japanese version shall prevail. This translation is subject to change without notice. Japan Exchange Group, Inc., Tokyo Stock Exchange, Inc., Nikkei Inc. and/or their affiliates shall individually or jointly accept no responsibility or liability for damage or loss caused by any error, inaccuracy, misunderstanding, or changes with regard to this translation. (Reference Translation) 1 Copyright©2018- by Tokyo Stock Exchange, Inc. and Nikkei Inc. All rights reserved Table of Contents Record of Changes............................................................................................................... 2 Introduction........................................................................................................................... 3 I. Outline of the Index........................................................................................................... 4 II. Index Calculation.............................................................................................................. 5 1. Outline............................................................................................................................ 5 2. Formula.......................................................................................................................... 5...

JPX-Nikkei Mid and Small Cap Index Guidebook December 17,2018 Tokyo Stock Exchange, Inc. Nikkei Inc. Published: December 17, 2018 DISCLAIMER: This translation may be used for reference purposes only. This English version is not an official translation of the original Japanese document. In cases where any differences occur between the English version and the original Japanese version, the Japanese version shall prevail. This translation is subject to change without notice. Tokyo Stock Exchange, Inc., Nikkei Inc. and/or their affiliates shall individually or jointly accept no responsibility or liability for damage or loss caused by any error, inaccuracy, misunderstanding, or changes with regard to this translation. (Reference Translation) 1 Copyright©2018- by Tokyo Stock Exchange, Inc., and Nikkei Inc. All rights reserved Table of Contents Introduction........................................................................................................................... 3 I. Outline of the Index........................................................................................................... 4 II. Index Calculation.............................................................................................................. 5 1. Outline............................................................................................................................ 5 2. Formula.......................................................................................................................... 5 3. Stock Price Used for ...

[Contact] Information Services, Tokyo Stock Exchange, Inc. (Tel:050-3377-7754, Email:index@jpx.co.jp) Index Business Office, Nikkei Inc. (Tel:03-6256-7341, Email:index@nex.nikkei.co.jp) Calculation of JPX-Nikkei Index 400 and JPX-Nikkei Mid and Small Cap Index in Relation to Shares of Takeda Pharmaceutical Company Limited and LIFULL Co., Ltd. December 17, 2018 Tokyo Stock Exchange, Inc. Nikkei Inc. Takeda Pharmaceutical Company Limited (Code: 4502), a constituent of JPX-Nikkei Index 400, and LIFULL Co., Ltd. (Code: 2120), a constituent of JPX-Nikkei Mid and Small Cap Index, are respectively scheduled to issue new shares to be additionally listed on Tokyo Stock Exchange, Inc. on January 10, 2019. In connection with the additional listing of these new shares, the calculation of these indices shall be handled as indicated in the table below, taking into consideration factors such as convenience for indices ...

Amendment to Program Information Credit Suisse International 2 AMENDMENT TO PROGRAM INFORMATION Type of Information: Amendment to Program Information Date of Announcement: 11 December 2018 Issuer Name: Credit Suisse International Name and Title of Representative: David Mathers Chief Executive Officer Address of Head Office: One Cabot Square, London E14 4QJ, UK Telephone: +44 (0)20 7888 8888 Contact Person: Attorney-in-Fact: Eiichi Kanda, Attorney-at-law Chihiro Ashizawa, Attorney-at-law Yasuaki Dote, Attorney-at-law Clifford Chance (Gaikokuho Kyodo Jigyo) Palace Building, 3rd floor 1-1, Marunouchi 1-chome Chiyoda-ku, Tokyo 100-0005 Telephone: 81-3-6632-6600 Address of Website for Announcement: https://www.jpx.co.jp/english/equities/products/tpbm/announc ement/index.html Information on initial Program Information: Date of Announcement: 26 April 2018 Scheduled Issuance Period: 27 April 2018 to 26 April 2019 Maximum Outstanding Issuance Amount: Unlimited This amendment is filed to ...

Amendment to Program Information Credit Suisse International 1 AMENDMENT TO PROGRAM INFORMATION Type of Information: Amendment to Program Information Date of Announcement: 11 December 2018 Issuer Name: Credit Suisse International Name and Title of Representative: David Mathers Chief Executive Officer Address of Head Office: One Cabot Square, London E14 4QJ, UK Telephone: +44 (0)20 7888 8888 Contact Person: Attorney-in-Fact: Eiichi Kanda, Attorney-at-law Chihiro Ashizawa, Attorney-at-law Yasuaki Dote, Attorney-at-law Clifford Chance (Gaikokuho Kyodo Jigyo) Palace Building, 3rd floor 1-1, Marunouchi 1-chome Chiyoda-ku, Tokyo 100-0005 Telephone: 81-3-6632-6600 Address of Website for Announcement: https://www.jpx.co.jp/english/equities/products/tpbm/announc ement/index.html Information on initial Program Information: Date of Announcement: 20 August 2018 Scheduled Issuance Period: 21 August 2018 to 20 August 2019 Maximum Outstanding Issuance Amount: Unlimited This amendment is filed to ...

(Form 8) Specified Securities Information ING Groep N.V. ING Bank N.V. SPECIFIED SECURITIES INFORMATION Type of Information: Specified Securities Information Date of Announcement: 7 December 2018 Company Names: ING Groep N.V. ING Bank N.V. Name and Title of Representative: D.E. Haring, Principal Treasury Manager Address of Main Office: Bijlmerplein 888 1102 MG Amsterdam Zuid-Oost, the Netherlands Telephone: +31(20) 563 8008 Contact Persons: Attorney-in-Fact: Eiichi Kanda, Attorney-at-law Chihiro Ashizawa, Attorney-at-law Takuya Yuasa, Attorney-at-law Keisuke Otsuka, Attorney-at-law Clifford Chance (Gaikokuho Kyodo Jigyo) Address: Palace Building, 3rd floor 1-1, Marunouchi 1-chome Chiyoda-ku, Tokyo 100-0005 Telephone: 81-3-6632-6600 Type of Securities: Senior Bonds Total Issuance Value of Securities: ING Groep N.V. Japanese Yen TOKYO PRO-BOND Market Listed Bonds–First Series (2018): JPY 107,500,000,000 ING Groep ...

1 Notes on Media Briefing by Akira Kiyota, Director and Representative Executive Officer, Group CEO, Japan Exchange Group, Inc., on March 30, 2018 I have three topics to report today. First, I would like to talk about the revisions to Japan’s Corporate Governance Code on the basis of the recommendations made by the Council of Experts Concerning the Follow-up of Japan’s Stewardship Code and Japan’s Corporate Governance Code. Since October 2017, said council, for which the FSA and TSE are the joint secretariat, has verified the progress of corporate governance reform. There was an evaluation that there has been a certain degree of progress in corporate governance reform due in part to the formulation of Japan’s Corporate Governance Code. On the other hand, it was pointed out that companies’compliance with the code remains superficial, not accompanied by substance, and that the engagement between companies ...

1 Notes on Media Briefing by Akira Kiyota, Director and Representative Executive Officer, Group CEO, Japan Exchange Group, Inc., on April 27, 2018 There are three items on the agenda for today. I would like to first present JPX's financial results for the fiscal year ended March 2018. Operating revenue was JPY 120.7 billion, operating income JPY 71.7 billion, and net income (attributable to owners of the parent company) JPY 50.4 billion. Expanding more on matters of revenue, operating revenue was up year on year to JPY 12.8 billion as trading volume of cash equities and derivatives were both higher than the previous year. Operating expenses increased by approximately JPY 700 million to JPY 50.9 billion from the previous fiscal year. This is a result of a year-on-year increase in expenses related to the revenue increase. Thus, while expenses slightly increased, revenue ...